Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 12/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 12/20 | 1.00 |
| ▸ | MAPT | P10636 | 4/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | SLFN12 | Q8IYM2 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | GALR3 | O60755 | 3/20 | 0.78 |
| ▸ | GAA | P10253 | 1/20 | 0.78 |
| ▸ | THRB | P10828 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | PDE4A | P27815 | 2/20 | 0.49 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.49 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.49 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29609389 | 1.00 | PDE3B (1.00) | PDE3BPDE3AMAPTALDH1A1SLFN12 | |
| SCHEMBL16156956 | 1.00 | PDE3B (1.00) | PDE3BPDE3AMAPTALDH1A1SLFN12 | |
| SCHEMBL29491026 | 1.00 | PDE3B (1.00) | PDE3BPDE3AMAPTALDH1A1SLFN12 | |
| SCHEMBL16156971 | 1.00 | PDE3B (1.00) | PDE3BPDE3AMAPTALDH1A1SLFN12 | |
| SCHEMBL10333380 | 0.90 | PDE3B (0.82) | PDE3BPDE3AMAPTALDH1A1SLFN12 | |
| SCHEMBL17446927 | 0.88 | MAPT (0.79) | PDE3BPDE3AMAPTALDH1A1SLFN12 | |
| SCHEMBL17446945 | 0.88 | MAPT (0.79) | PDE3BPDE3AMAPTALDH1A1SLFN12 | |
| SCHEMBL10333665 | 0.88 | GALR3 (1.00) | PDE3BPDE3AMAPTALDH1A1SLFN12 | |
| SCHEMBL10699653 | 0.87 | PDE3B (0.76) | PDE3BPDE3AMAPTALDH1A1SLFN12 | |
| SCHEMBL17446972 | 0.84 | PDE3B (0.72) | PDE3BPDE3AMAPTALDH1A1SLFN12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250041294-A1 | Synergistic compositions for use in the treatment of cancer | SARTAR THERAPEUTICS OY (FI) | 2025-02-06 | — | — | US | claimed |
| EP-4444314-A1 | SYNERGISTIC COMPOSITIONS FOR USE IN THE TREATMENT OF CANCER | Sartar Therapeutics Oy (FI) | 2024-10-16 | — | — | EP | claimed |
| CN-118354773-A | Synergistic composition for the treatment of cancer | 萨达治疗公司 | 2024-07-16 | — | — | CN | claimed |
| WO-2023105119-A1 | SYNERGISTIC COMPOSITIONS FOR USE IN THE TREATMENT OF CANCER | SARTAR THERAPEUTICS OY (FI) | 2023-06-15 | — | — | WO | claimed |
| US-20250041294-A1 | Synergistic compositions for use in the treatment of cancer | SARTAR THERAPEUTICS OY (FI) | 2025-02-06 | — | — | US | disclosed |
| US-20240366620-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR CANCER PATIENT STRATIFICATION AND CANCER TREATMENT | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2024-11-07 | — | — | US | disclosed |
| EP-4444314-A1 | SYNERGISTIC COMPOSITIONS FOR USE IN THE TREATMENT OF CANCER | Sartar Therapeutics Oy (FI) | 2024-10-16 | — | — | EP | disclosed |
| EP-3334404-B1 | COMPOSITIONS AND METHODS FOR CANCER EXPRESSING PDE3A AND SLFN12 | BROAD INST INC (US) | 2024-09-18 | — | — | EP | disclosed |
| US-12053476-B2 | Compounds, compositions and methods for cancer patient stratification and cancer treatment | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2024-08-06 | — | — | US | disclosed |
| CN-118354773-A | Synergistic composition for the treatment of cancer | 萨达治疗公司 | 2024-07-16 | — | — | CN | disclosed |
| WO-2023105119-A1 | SYNERGISTIC COMPOSITIONS FOR USE IN THE TREATMENT OF CANCER | SARTAR THERAPEUTICS OY (FI) | 2023-06-15 | — | — | WO | disclosed |
| CN-108883112-B | Compounds, compositions and methods for cancer patient stratification and cancer treatment | 拜耳医药股份公司 | 2022-07-26 | — | — | CN | disclosed |
| CN-114699528-A | Compositions and methods for PDE3A or SLFN12 expressing cancers | 布罗德研究所股份有限公司 | 2022-07-05 | — | — | CN | disclosed |
| CN-114601837-A | Compounds, compositions and methods for cancer patient stratification and cancer treatment | 拜耳医药股份公司 | 2022-06-10 | — | — | CN | disclosed |
| CN-108366947-B | Compositions and methods for PDE3A or SLFN12 expressing cancers | 布罗德研究所股份有限公司 | 2022-03-29 | — | — | CN | disclosed |
| US-20220071995-A1 | COMPOSITIONS AND METHODS FOR CANCER EXPRESSING PDE3A OR SLFN12 | THE BROAD INSTITUTE, INC. (US) | 2022-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220071995-A1 | COMPOSITIONS AND METHODS FOR CANCER EXPRESSING PDE3A OR SLFN12 | SMPD3, SMPD1, SMPD2 | PDE3B 21/4885PDE3A 15/4885MAPT 4019/4885 |
| US-12053476-B2 | Compounds, compositions and methods for cancer patient stratification and cancer treatment | CREB1, CREBBP, SLFN12 | PDE3B 11/4885PDE3A 7/4885MAPT 4426/4885 |
| US-20240366620-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR CANCER PATIENT STRATIFICATION AND CANCER TREATMENT | CREB1, CREBBP, SLFN12 | PDE3B 11/4885PDE3A 7/4885MAPT 4426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.